₹ 3,179.09 Cr
1.91%
BSE Healthcare TRI
INF740KA1LD8
100.0
100.0
100
Mr. Chirag Dagli
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| DSP Healthcare Fund - Regular Plan - Growth | -5.86 | 21.29 | 14.75 |
| Benchmark | - | - | - |
Equity
Debt
Others
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 8.85 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 8.63 |
| IPCA LABORATORIES LIMITED EQ NEW FV RE .1/- | 7.76 |
| Globus Medical Inc | 6.89 |
| LAURUS LABS LIMITED EQ NEW FV RS. 2/- | 6.21 |
| Illumina Inc | 5.93 |
| SUVEN PHARMACEUTICALS LIMITED EQ | 5.27 |
| GLAND PHARMA LIMITED EQ NEW FV Re.1/- | 5.1 |
| Sai Life Sciences Limited | 4.99 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 4.49 |
| Sector | Holdings (%) |
|---|---|
| Healthcare | 77.83 |
| Financial Services | 1.5 |
| Consumer Services | 0.49 |